News for Hepion Pharmaceuticals, Inc. (HEPA)

Hepion Pharmaceuticals (HEPA) has disclosed that it will be delisted from the Nasdaq Stock Market following a decision by the Nasdaq Hearings Panel. The company

MORRISTOWN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (HEPA), a clinical stage biopharmaceutical company that had been developing a

Hepion Pharmaceuticals (HEPA) receives delisting notification from Nasdaq due to compliance issues. The stock will be suspended on Nasdaq and transition

Pharma Two B's P2B001 shows promising results for early-stage Parkinson's patients. Hepion Pharmaceuticals Inc. (HEPA) has a significant upside potentia

Summary: Hepion Pharmaceuticals, Inc. (HEPA) is engaging in a significant public offering to raise approximately $9 million. The company's shares could s

Shares Expected to Begin Trading on Split-Adjusted Basis on March 18, 2025 MORRISTOWN, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc.

Shares of Intel Corporation INTC rose sharply in today's pre-market trading after the company announced a new chief executive officer. The company said its boa...

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.30%

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 250 points on Wednesday. The Dow traded up 0.27% to 44,146.86 whi...

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Wednesday. The Dow traded up 0.30% to 44,159.42 whil...

**media[521489]**

Hepion Pharmaceuticals launches $9 million stock offering

Hepion Pharmaceuticals, Inc. (HEPA) Wednesday announced a mutual decision to terminate the merger agreement with Rehovot, Israel-based Pharma Two B Ltd. The Edison, New Jersey-based clinical stage biopharmaceutical company said there would be no termination fee.

EDISON, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. ( HEPA) (the ”œCompany” or ”œHepion”), a clinical stage biopharmaceutical c

Pooled data analysis of efficacy and safety from Phase 2b and Phase 3 data sets in patients with early-stage Parkinson's disease (PD) support P2B001 as a first

**media[484359,484360]**

Transaction Creates Opportunity to Share in Potential Upside of Pharma Two B's Late-Clinical Stage Candidate to Treat Parkinson's Disease Hepion's Board Unanim

Shares of Deckers Outdoor Corporation DECK rose sharply in today's pre-market trading after the company reported better-than-expected second-quarter financial r...

The surge in liver disease therapeutics demand stems mainly from a growing population afflicted with liver ailments, elevated alcohol intake, and unhealthy...